Zydus Cadila settles patent litigation relating to Allergan’s DELZICOL

05 Dec 2016 Evaluate

Zydus Cadila, an innovation-driven global pharmaceutical company, has settled the patent litigation relating to Allergan’s DELZICOL (mesalamine). As a result of the settlement, and if approved by FDA, its US subsidiary, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of DELZICOL in the United States beginning on March 1, 2020, or earlier under certain circumstances.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.


 

Zydus Lifesciences Share Price

881.95 -2.90 (-0.33%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×